PrecisionLife’s powerful analytics platform interprets complex biological data and other influences to change the way the world predicts, prevents and treats chronic diseases, developing more personalised treatment options and furthering our understanding of how foods, medicines and healthcare can be combined to improve peoples’ lives.
PrecisionLife has discovered hundreds of opportunities for existing drugs to be extended into new disease areas to treat patients with unmet medical need faster, more cost effectively, and with a greater probability of success. For example, it was the first to identify an existing drug – dutasteride – as a treatment for severe COVID-19, which has kept thousands of people out of ICU.
The company's platform also identified the first ever genetic drivers of ME/CFS paving the way for better diagnostics and personalized treatments. Similar studies are helping in the fight against asthma, Alzheimer's, ALS and breast cancer.